Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
2026-03-17T12:16:31.000Z - 2 months ago
Mar 17, 2026, 8:08 AM EDT - 2 months ago
2026-02-17T13:55:30.000Z - 3 months ago
Feb 17, 2026, 8:44 AM EST - 3 months ago
2026-02-11T11:16:00.000Z - 3 months ago
Oct 30, 2025, 10:04 AM EDT - 6 months ago
2025-08-04T17:30:33.000Z - 10 months ago
2025-08-04T17:25:16.000Z - 10 months ago
2025-07-28T11:35:07.000Z - 10 months ago
Jul 28, 2025, 7:30 AM EDT - 10 months ago
2025-07-25T12:40:53.000Z - 10 months ago
Jul 25, 2025, 8:31 AM EDT - 10 months ago
2025-07-24T12:51:27.000Z - 10 months ago
Jul 24, 2025, 8:31 AM EDT - 10 months ago
2025-07-22T17:45:39.000Z - 10 months ago
2025-07-22T17:35:35.000Z - 10 months ago
2025-07-22T17:35:29.000Z - 10 months ago
Jul 22, 2025, 1:30 PM EDT - 10 months ago
2025-06-30T14:47:52.000Z - 11 months ago
2025-06-30T14:47:46.000Z - 11 months ago
2025-06-25T18:00:26.000Z - 11 months ago
2025-06-25T17:55:16.000Z - 11 months ago
2025-06-24T20:55:20.000Z - 11 months ago
2025-06-24T20:55:09.000Z - 11 months ago
2025-06-12T14:50:12.000Z - 11 months ago
2025-06-12T14:45:12.000Z - 11 months ago